国产ECMO标杆企业汉诺医疗开启高端医疗装备自主新篇章

Core Insights - Shenzhen Hanno Medical Technology Co., Ltd. has submitted its application for listing on the Sci-Tech Innovation Board, aiming to raise 1.06 billion yuan for R&D, production, marketing, and working capital [1] - The company is one of the few globally to have a complete layout of ECMO devices and consumables, reflecting the Sci-Tech Innovation Board's support for unprofitable hard tech enterprises [1] Financial Performance - Hanno Medical's revenue is projected to grow from 29.83 million yuan in 2023 to 49.31 million yuan in 2024, with 37.36 million yuan achieved in the first half of 2025 [1] - The company's losses are narrowing, decreasing from 341 million yuan in 2023 to 82.27 million yuan in the first half of 2025 [1] Innovation and Technology - The company has developed seven core technologies and holds 38 invention patents, establishing a strong patent barrier [2] - The Lifemotion® ECMO system was approved for market entry in 2023, breaking the long-standing technological monopoly of countries like the US, Germany, and Italy [2] International Expansion - Hanno Medical's products are now used in over 140 hospitals across China and have achieved market entry in Brazil and South Africa [3] - The receipt of the EU CE MDR certification signifies that the quality and effectiveness of the company's high-end medical equipment meet international standards [3] Market Potential - The ECMO market in China is expected to grow from 960 million yuan in 2024 to 3.71 billion yuan by 2030, with a compound annual growth rate of 25.2% [4] - The global ECMO market is projected to reach 5.8 billion USD by 2035, highlighting the increasing demand for stable suppliers amid a fragile global supply chain [4] Business Model - Hanno Medical employs a "device-first, consumable-driven" business model, leading the domestic market for new ECMO devices due to performance and cost advantages [4] - The continuous consumption of high-value consumables ensures predictable cash flow, with plans to replicate this model in international markets [4]